Browsing Tag
everolimus
2 posts
Can Roche’s 62% success rate in breast cancer trials spark the next oncology breakthrough?
Roche’s new oral breast-cancer therapy cut disease-progression risk by up to 62% in late-stage trials. Find out how it could reshape treatment in 2025.
Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial
Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical…